PHASE I TRIALS FOR PSORAXINE

Astralis has begun Phase I clinical trial for Psoraxine for the treatment of moderate plaque psoriasis.

Related Videos
Related Content

25.1% of Patients Cited “Less Noticeable” Vitiligo in Recent Study

March 21st 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Indoor Tanning and Melanoma

March 21st 2023

The Cutaneous Connection: Using the Color Wheel to Discuss Nutrition

March 26th 2022

Oral Ivarmacitinib Demonstrates Significant Atopic Dermatitis Improvement

March 21st 2023

Annual Meeting Session Highlights Clinical Pearls in Medical Dermatology

March 21st 2023

25.1% of Patients Cited “Less Noticeable” Vitiligo in Recent Study

March 21st 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Indoor Tanning and Melanoma

March 21st 2023

The Cutaneous Connection: Using the Color Wheel to Discuss Nutrition

March 26th 2022

Oral Ivarmacitinib Demonstrates Significant Atopic Dermatitis Improvement

March 21st 2023

Annual Meeting Session Highlights Clinical Pearls in Medical Dermatology

March 21st 2023

25.1% of Patients Cited “Less Noticeable” Vitiligo in Recent Study

March 21st 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Indoor Tanning and Melanoma

March 21st 2023

The Cutaneous Connection: Using the Color Wheel to Discuss Nutrition

March 26th 2022

Oral Ivarmacitinib Demonstrates Significant Atopic Dermatitis Improvement

March 21st 2023

Annual Meeting Session Highlights Clinical Pearls in Medical Dermatology

March 21st 2023
© 2023 MJH Life Sciences

All rights reserved.